DDrare: Database of Drug Development for Rare Diseases

告示番号	疾患名（ページ内リンク）	臨床試験数
218	アルポート症候群	1

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT02855268 (ClinicalTrials.gov)	November 2, 2019	28/7/2016	Study of SAR339375 in Patients With Alport Syndrome	A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Efficacy, Pharmacodynamics, and Pharmacokinetics of SAR339375 for Subcutaneous Injection Administered Every Week in Patients With Alport Syndrome	Alport's Syndrome	Drug: Lademirsen (SAR339375);Drug: Placebo	Genzyme, a Sanofi Company	NULL	Recruiting	18 Years	55 Years	All	45	Phase 2	United States;Australia;China;France;Germany;Spain;United Kingdom

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

NCT02855268
(ClinicalTrials.gov)

November 2, 2019

28/7/2016

Study of SAR339375 in Patients With Alport Syndrome

A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Efficacy, Pharmacodynamics, and Pharmacokinetics of SAR339375 for Subcutaneous Injection Administered Every Week in Patients With Alport Syndrome

Alport's Syndrome

Drug: Lademirsen (SAR339375);Drug: Placebo

Genzyme, a Sanofi Company

NULL

Recruiting

18 Years

55 Years

All

Phase 2

United States;Australia;China;France;Germany;Spain;United Kingdom